Acepromazine (PromAce)

Acepromazine, commonly known by the brand name PromAce and also called ACP, is a phenothiazine tranquilizer that has been used in veterinary medicine for decades as a sedative and pre-anesthetic agent. In rabbit medicine, acepromazine serves as one option for sedation and chemical restraint, though it has largely been superseded by newer medications with more favorable pharmacological profiles for this species. Despite this shift toward alternatives, acepromazine remains available and may be used in certain clinical situations, particularly when other sedatives are unavailable or contraindicated. Understanding this medication helps rabbit owners make informed decisions in consultation with their veterinarian.

Acepromazine produces its sedative effects primarily through blockade of dopamine receptors in the central nervous system, resulting in a calm, tranquil state in treated animals. Unlike true anesthetics, acepromazine does not produce unconsciousness or analgesia at clinical doses, but rather creates a state of reduced reactivity and apparent indifference to surroundings. The medication also has significant effects on the cardiovascular system, producing vasodilation and reduced blood pressure through alpha-adrenergic receptor blockade. This cardiovascular effect is an important consideration in rabbits, as these small prey animals may be more susceptible to hypotensive effects. The sedative effect typically lasts several hours, considerably longer than many alternative medications.

Acepromazine is available as both an injectable solution and oral tablets, though the injectable form is most commonly used in veterinary practice for rabbit patients. The injectable preparation can be administered intramuscularly, intravenously, or subcutaneously depending on the desired onset time and clinical situation. Oral administration is possible but results in variable absorption and less predictable effects compared to injection. The medication is typically administered in a clinical setting rather than dispensed for home use, as proper patient monitoring during the sedation period is important for safety. Unlike benzodiazepines and alpha-2 agonists, acepromazine does not have a specific reversal agent, meaning the effects must be allowed to wear off naturally once the medication is given.

While acepromazine has a long history of use in veterinary medicine, rabbit-savvy veterinarians often prefer alternative sedatives with shorter durations of action, reversibility, and less pronounced cardiovascular effects. Medications such as midazolam, dexmedetomidine, and alfaxalone have become first-line choices for rabbit sedation in many practices. However, acepromazine remains a viable option when these alternatives are not available or when its specific characteristics offer advantages in particular clinical scenarios. Rabbit owners should discuss sedation options with their veterinarian to understand which medication is most appropriate for their pet's specific situation.

The primary indication for acepromazine in rabbit medicine is sedation and chemical restraint for procedures that require a calm, tractable patient. Rabbits are prey animals prone to extreme stress responses when handled or restrained, and this stress can pose significant risks including dangerous hyperthermia, cardiovascular complications, and self-injury from violent struggling. Acepromazine reduces this fear response by producing a state of mental tranquility that allows for safer handling. The medication has been used historically for various procedures including physical examinations of fractious patients, minor procedures not requiring anesthesia, and restraint for diagnostic imaging.

Pre-anesthetic sedation represents another traditional use of acepromazine in rabbit patients. When administered before general anesthesia, acepromazine reduces the stress of hospital admission and catheter placement while decreasing the doses of induction and maintenance anesthetics required. This drug-sparing effect can contribute to smoother anesthetic inductions and more stable maintenance. However, many modern rabbit anesthesia protocols have moved away from acepromazine in favor of medications that provide both sedation and analgesia, such as opioid combinations or alpha-2 agonists, which offer additional benefits not provided by acepromazine alone.

Management of aggressive or extremely frightened rabbits may occasionally warrant acepromazine use when other approaches are insufficient. Some rabbits become so distressed during veterinary visits that they pose injury risks to themselves and staff, and in these cases, sedation becomes necessary for any productive interaction. Acepromazine can provide adequate calming in these situations, though the long duration of effect means extended recovery monitoring is required. For rabbits with documented extreme anxiety, veterinarians may consider whether pretreatment with oral anxiolytics before the visit might reduce the need for injectable sedation upon arrival.

Transportation sedation is an application where acepromazine has historically been used, particularly for long-distance transport of show rabbits or relocation of pet rabbits. The prolonged duration of action can be advantageous for extended transport times. However, the cardiovascular effects of acepromazine, including hypotension, raise concerns about using this medication in animals that may be exposed to temperature extremes or other transport stressors. Modern practice generally favors shorter-acting, reversible medications when sedation during transport is deemed necessary.

Veterinarians selecting sedation protocols for rabbit patients weigh multiple factors when considering acepromazine versus alternatives. The lack of analgesia means acepromazine is not appropriate as the sole agent for painful procedures. The irreversibility means that once administered, the effects cannot be quickly terminated if complications arise. The prolonged duration extends recovery time and increases the risk of complications such as hypothermia and gastrointestinal stasis. For these reasons, acepromazine is often reserved for situations where its specific characteristics offer advantages or where preferred alternatives are unavailable.

Acepromazine dosing in rabbits requires careful veterinary calculation based on the individual patient's weight, health status, and the degree of sedation required. The therapeutic index of acepromazine in rabbits is narrower than in some other species, and these small animals may be more sensitive to the cardiovascular effects of the medication. Accurate weighing is essential, as even small errors in estimated body weight can result in significant relative over- or under-dosing. The veterinarian considers concurrent medications, the rabbit's temperament and previous sedation history, and the specific procedure being performed when determining the appropriate dose.

General dosing guidelines for acepromazine in rabbits typically range from approximately 0.1 to 0.5 milligrams per kilogram administered intramuscularly or subcutaneously, though exact doses vary based on the clinical situation and individual patient factors. Lower doses within this range may provide adequate calming for minor procedures or mildly anxious patients, while higher doses may be needed for more profound sedation or particularly fractious individuals. Some veterinarians use even lower doses in combination with other sedatives or analgesics to achieve balanced sedation while minimizing the cardiovascular effects associated with acepromazine. The dose selected must always be individualized to the specific patient.

Treatment with acepromazine for sedation is typically a single administration rather than repeated dosing. The onset of action following intramuscular injection is approximately fifteen to thirty minutes, with peak effects occurring at about one hour and lasting two to four hours or longer depending on the dose. This prolonged duration distinguishes acepromazine from many alternative sedatives and is important to consider when planning procedures and recovery monitoring. For extremely long procedures, additional doses are generally not recommended due to cumulative effects and prolonged recovery; instead, alternative sedation methods may be employed.

Acepromazine administration routes in rabbits include intramuscular, subcutaneous, and intravenous injection, with intramuscular being most common for routine sedation. The lumbar muscles or quadriceps provide suitable injection sites in rabbit patients. Intravenous administration produces more rapid onset but requires venous access, which may be challenging in an unsedated rabbit. Subcutaneous administration is possible but may result in slower and less predictable absorption compared to intramuscular injection. Oral acepromazine is available but is rarely used in rabbits due to variable absorption and unpredictable effects. Regardless of route, administration is performed by veterinary staff in a clinical setting where appropriate monitoring is available.

Missed doses are not a consideration with acepromazine as this medication is administered as single doses for specific procedures rather than as ongoing therapy. If a procedure is cancelled after acepromazine has been given, the rabbit must be monitored through the sedation period regardless, as the medication cannot be reversed. Recovery monitoring includes assessment of responsiveness, body temperature, cardiovascular status, and when the rabbit begins to recover, ability to move and eat normally. Prolonged recovery requires extended monitoring and supportive care.

Complete recovery from acepromazine sedation should be confirmed before the rabbit is discharged to go home. The rabbit should be able to maintain normal body temperature, move in a coordinated manner, and show interest in food and water. Due to the prolonged sedation period, many rabbits may not be ready for discharge on the same day as procedures involving acepromazine. Owners should receive specific instructions about monitoring at home and signs that would warrant return to the veterinary clinic.

Acepromazine's side effect profile in rabbits reflects its mechanism of action and the physiological characteristics of these small prey animals. Most rabbits experience the expected sedative effects, but additional effects related to cardiovascular and thermoregulatory function are common and require monitoring. Understanding the potential side effects helps veterinary staff provide appropriate supportive care during the sedation period and enables proper preparation for managing complications if they occur. The long duration of acepromazine's effects means that side effects, when they occur, may persist for extended periods.

The most common side effects of acepromazine in rabbits are directly related to its intended sedative properties and include prolonged drowsiness, reduced coordination, and decreased responsiveness to stimuli. These effects are expected and should not cause alarm when they fall within normal parameters for the dose administered. Hypotension is a frequent cardiovascular effect resulting from alpha-adrenergic blockade and vasodilation. In rabbits, reduced blood pressure may manifest as pale mucous membranes, prolonged capillary refill time, or weakness. Temperature regulation is often impaired, with hypothermia being a significant concern, particularly in small rabbits or those in cool environments. Reduced fecal output during the sedation period is common and typically resolves as the rabbit recovers.

Moderate side effects requiring intervention include significant hypothermia, pronounced cardiovascular depression, or prolonged sedation extending well beyond expected duration. Hypothermia is managed through external warming using warmed surfaces, warm air blankets, or other appropriate methods while avoiding burns. Significant hypotension may require intravenous fluid support or, in severe cases, vasopressor medications. Any rabbit remaining deeply sedated more than six hours after acepromazine administration should be evaluated for potential complications. Gastrointestinal stasis can develop as a secondary complication when rabbits are unable to eat for extended periods during sedation; supportive care including gentle abdominal massage, fluid therapy, and nutritional support may be needed.

Serious side effects requiring emergency intervention are less common but include severe cardiovascular collapse, respiratory depression, and extreme hypothermia. Because acepromazine cannot be reversed, management of serious complications relies on supportive care measures. Severe hypotension may require aggressive fluid therapy and vasopressor support. Respiratory depression, if it occurs, may necessitate supplemental oxygen or assisted ventilation. Seizures have been reported rarely with acepromazine use in various species, though this is uncommon in rabbits. Any rabbit showing signs of cardiovascular collapse, severe respiratory distress, or seizure activity requires immediate intensive care.

Idiosyncratic and rare reactions to acepromazine include paradoxical excitement rather than sedation, prolonged unconsciousness, and potential effects on future drug sensitivity. Some individual rabbits may experience enhanced sensitivity to acepromazine, resulting in exaggerated effects from standard doses. Rabbits that have had adverse reactions to acepromazine should have this documented for future reference, as alternative sedatives would be preferred for subsequent procedures. The lack of reversal agent for acepromazine means that managing unexpected or severe reactions is more challenging than with reversible alternatives like benzodiazepines or alpha-2 agonists.

Acepromazine is contraindicated in rabbits with known hypersensitivity to phenothiazine medications. While true allergic reactions to acepromazine are uncommon, any rabbit that has previously experienced an adverse reaction to acepromazine or related phenothiazines should not receive the medication again. Previous reactions might include unexpected severity of effects, prolonged recovery, cardiovascular complications, or other unexplained adverse events. Owners should inform veterinarians of any previous sedation problems their rabbit has experienced, even if the specific medication used is unknown, as this information guides safer drug selection.

Cardiovascular compromise represents an important contraindication for acepromazine use in rabbits. The alpha-adrenergic blocking effects of acepromazine produce vasodilation and hypotension that could be dangerous in patients with pre-existing cardiac disease, hypotension, or hypovolemia. Rabbits in shock, those with significant dehydration, or those that have experienced recent blood loss should not receive acepromazine until stabilized. The cardiovascular depression produced by acepromazine cannot be reversed pharmacologically, making this medication particularly risky in cardiovascularly compromised patients. Alternative sedatives with less pronounced cardiovascular effects and available reversal agents are preferred for rabbits with cardiac concerns.

Pregnancy and nursing present relative contraindications to acepromazine use in rabbits. While specific teratogenicity studies in rabbits are limited, phenothiazines cross the placental barrier and could potentially affect developing fetuses. The cardiovascular effects could also compromise placental blood flow. Nursing does should avoid acepromazine as the drug is excreted in milk and could affect neonates. Elective procedures requiring sedation should ideally be postponed until after kindling and weaning are complete. Emergency situations may still warrant acepromazine use after careful risk-benefit assessment if safer alternatives are not available.

Severe hepatic dysfunction affects acepromazine metabolism and elimination, potentially resulting in prolonged and intensified effects. Rabbits with known liver disease require careful evaluation before acepromazine is considered, and alternative sedatives may be more appropriate. The already prolonged duration of acepromazine effects could be extended significantly in hepatically impaired patients. Additionally, rabbits experiencing active gastrointestinal stasis should generally not receive sedatives that could further compromise gut motility, as the combination could worsen this potentially life-threatening condition. Seizure history, while not an absolute contraindication, warrants caution as acepromazine may lower seizure threshold in susceptible individuals.

Comprehensive disclosure of all medications, supplements, and treatments the rabbit is receiving is essential before acepromazine administration. Drug interactions can significantly affect both the safety and efficacy of sedation, potentially increasing risks or altering expected responses. This includes any prescription medications, over-the-counter products, herbal supplements, and treatments administered by other veterinary providers. Because acepromazine affects multiple receptor systems and is metabolized hepatically, various interactions are possible with commonly used medications.

Acepromazine has significant interactions with other central nervous system depressants, including opioids, benzodiazepines, alpha-2 agonists, and general anesthetics. When combined with these medications, the sedative and cardiovascular effects are additive or synergistic, potentially resulting in deeper sedation and more pronounced hypotension than expected from either drug alone. While these combinations are sometimes used intentionally in balanced anesthesia protocols, dose reductions of all components are typically necessary to avoid excessive effects. Veterinarians experienced in rabbit anesthesia design combination protocols that maximize benefits while managing cumulative risks.

Cardiovascular medications interact importantly with acepromazine due to its alpha-blocking properties. Concurrent use of other vasodilators or antihypertensive medications could produce additive hypotensive effects, potentially resulting in dangerous drops in blood pressure. Conversely, medications with vasoconstrictor properties could partially counteract acepromazine's cardiovascular effects, though this interaction is not typically exploited therapeutically. Beta-blockers used concurrently with acepromazine require caution due to potential for excessive cardiovascular depression. Any rabbit on cardiovascular medications requires careful evaluation before acepromazine sedation.

Organophosphate compounds, including certain insecticides and antiparasitic medications, interact with acepromazine through effects on neuromuscular and CNS function. Rabbits recently treated with organophosphate products should not receive acepromazine until an appropriate washout period has elapsed. This is particularly relevant in rabbit medicine where various antiparasitic treatments might be used. Herbal supplements and natural calming products should be disclosed, as they could have additive sedative effects. Probiotics and digestive supplements commonly used in rabbit care do not have known significant interactions with acepromazine and can generally be continued during recovery to support gastrointestinal function.

General precautions for acepromazine use in rabbits emphasize the importance of appropriate patient selection, accurate dosing, and comprehensive monitoring throughout the sedation period. This medication should be administered only in veterinary settings where proper monitoring equipment and supportive care capabilities are available. Because acepromazine cannot be reversed, careful patient assessment before administration is critical to identify any factors that might increase risk. The veterinary team should have contingency plans for managing potential complications, including hypothermia, hypotension, and prolonged sedation.

Breed-specific considerations for acepromazine in rabbits relate primarily to body size differences affecting dosing precision and physiological reserves. Dwarf breeds including Netherland Dwarfs, Mini Rex, and Holland Lops require meticulous weight measurement and dose calculation because their small body mass provides less buffer against overdosing and they may have more limited cardiovascular reserves. Giant breeds such as Flemish Giants generally tolerate acepromazine well but require appropriate absolute doses based on their large body weight. No specific breed sensitivities to acepromazine have been documented in rabbits, though individual variation exists across all breeds. Brachycephalic rabbit breeds may warrant additional airway monitoring during sedation.

Environmental precautions during acepromazine sedation are particularly important due to the medication's effects on thermoregulation. Sedated rabbits should be maintained in a warm environment with supplemental heat sources if needed to prevent hypothermia. Active warming should be available immediately if body temperature drops. The rabbit should be positioned comfortably on padded surfaces with careful attention to body position to prevent aspiration and circulation compromise. In multi-pet facilities, sedated rabbits should be protected from disturbance by other animals. Monitoring should continue without interruption until recovery is complete.

Comprehensive monitoring during acepromazine sedation includes regular assessment of heart rate, respiratory rate, body temperature, blood pressure when possible, and level of sedation. Temperature monitoring is particularly critical given the high risk of hypothermia. Mucous membrane color and capillary refill time provide information about cardiovascular status. As the rabbit begins to recover, monitoring transitions to assessing coordination, ability to maintain normal posture, interest in food, and fecal production. Any deviation from expected recovery trajectory should prompt veterinary evaluation.

Special population considerations include geriatric rabbits, those with chronic health conditions, and debilitated patients. Elderly rabbits may have reduced cardiovascular reserves and hepatic function, making them more susceptible to acepromazine's effects and slower to recover. Young rabbits with immature organ systems may also respond unpredictably. Rabbits with chronic conditions including dental disease, E. cuniculi, or respiratory problems require individualized assessment. The irreversibility of acepromazine means that once administered to any special population patient, the commitment to supportive care through full recovery cannot be shortened.

Acepromazine injectable solution should be stored at controlled room temperature, typically between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit), protected from light and freezing. The medication should be kept in its original container until use. Injectable solutions should be inspected before each use for any signs of discoloration, precipitate formation, or contamination, and any vials showing abnormalities should be discarded. Multi-dose vials should be handled with aseptic technique to prevent contamination and should be discarded after the labeled beyond-use date or earlier if contamination is suspected.

Oral formulations of acepromazine, when prescribed, require similar storage at controlled room temperature away from heat and moisture. Tablets should be kept in a child-resistant container in a secure location away from the rabbit's living area and inaccessible to other household pets and children. While oral acepromazine is rarely used in rabbit patients due to variable absorption, any oral formulation that has been prescribed should be stored according to the veterinarian's or pharmacist's instructions. Expiration dates should be checked regularly and expired medication properly disposed of.

Safe handling of acepromazine requires appropriate precautions for personnel who may be exposed during preparation and administration. While acepromazine is not a controlled substance and does not carry the same abuse potential as some sedatives, proper handling technique protects both staff and patients. Accidental injection or significant skin absorption could produce sedation and hypotension in humans. Standard precautions including appropriate hand hygiene after handling and careful needle safety practices should be observed. Any accidental exposure should be reported and medical advice sought if concerning symptoms develop.

Disposal of unused acepromazine and expired products should follow proper pharmaceutical waste procedures. While not a controlled substance, acepromazine should not be disposed of in regular household trash or flushed down drains. Veterinary facilities dispose of pharmaceutical waste according to applicable regulations. For any acepromazine that has been dispensed to owners, unused medication should be returned to a pharmacy or veterinary facility for proper disposal rather than kept at home indefinitely.

Acepromazine use in rabbits has not been associated with specific documented breed sensitivities, and the medication is generally considered appropriate across all rabbit breeds when properly dosed and monitored. However, the diversity of rabbit breeds encompasses significant variation in body size, physiological characteristics, and temperament that can influence both the need for sedation and the response to medication. Veterinary professionals consider these breed-related factors when developing sedation protocols for individual patients.

Dwarf breed rabbits including Netherland Dwarfs, Holland Lops, Mini Rex, and Polish present specific considerations for acepromazine use related to their small body size. These breeds typically weigh between one and two kilograms, meaning that accurate weight measurement in grams is essential for proper dose calculation. Small rabbits have higher surface-area-to-volume ratios, making them more susceptible to hypothermia during sedation, and they may have relatively less cardiovascular reserve to compensate for acepromazine-induced hypotension. Careful monitoring with readily available warming support is particularly important for dwarf breed patients. The prolonged duration of acepromazine effects may be perceived as more problematic in these active small breeds.

Giant breeds such as Flemish Giants, Continental Giants, and British Giants tolerate acepromazine well when appropriate weight-based doses are calculated. The larger body mass generally provides more physiological reserve to buffer against cardiovascular effects and temperature fluctuations. However, the larger absolute doses required for giant breeds increase medication costs and may require larger volumes of injectable solution. Giant breed rabbits should be provided with appropriately sized recovery areas and may require additional padding and positioning support during sedation due to their body weight. Joint problems common in some giant breeds may affect positioning during procedures.

Breed-related temperament variations may influence decisions about sedation requirements, though individual variation within breeds is substantial. Some breeds have reputations for calmer dispositions and may require less pharmacological intervention for routine procedures, while breeds known for more reactive temperaments might benefit more from sedation. However, treatment decisions should be based on the individual rabbit's specific behavior history rather than breed generalizations. Age considerations span all breeds, with both very young and geriatric rabbits potentially showing modified responses to acepromazine requiring adjusted dosing and enhanced monitoring.

Alternative sedatives commonly used in rabbit medicine offer various advantages over acepromazine for different clinical situations, and understanding these options helps guide informed discussions with veterinary providers. Midazolam, a benzodiazepine, has become a preferred sedative for many rabbit-savvy veterinarians due to its shorter duration of action, reversibility with flumazenil, and minimal cardiovascular effects. The ability to reverse midazolam provides an important safety advantage, allowing rapid restoration of normal function if complications arise or when sedation is no longer needed. Midazolam can be administered via multiple routes including intranasal, making initial sedation less stressful for some patients.

Alpha-2 adrenergic agonists such as dexmedetomidine represent another alternative class with distinct advantages and considerations. These medications provide reliable sedation with useful analgesic properties not found with acepromazine or benzodiazepines. The availability of the reversal agent atipamezole allows controlled termination of effects when needed. However, alpha-2 agonists produce significant cardiovascular effects including bradycardia and initial hypertension followed by hypotension, requiring appropriate patient selection and monitoring. For rabbits requiring both sedation and pain management, alpha-2 agonists may offer advantages over acepromazine's tranquilization without analgesia.

Complementary approaches and supportive care should be considered alongside any sedation protocol in rabbit patients. Environmental modifications such as minimal handling, quiet surroundings, and covering the carrier with a towel can reduce stress without medication. Warming support is essential during any sedation to prevent hypothermia. Nutritional support including offering hay and appropriate foods immediately when the rabbit is alert enough to eat safely helps prevent gastrointestinal stasis that could develop from prolonged fasting during sedation. Probiotics may be administered to support gut flora, particularly after any period of stress or reduced food intake. When sedation is necessary, rabbit owners should work with a rabbit-savvy veterinarian to select the most appropriate medication and protocol for their individual pet's needs, considering factors such as the procedure required, the rabbit's health status, and the specific advantages and risks of each available option.